CN102198181A - Antithrombotic and thrombosis-eliminating preparation - Google Patents

Antithrombotic and thrombosis-eliminating preparation Download PDF

Info

Publication number
CN102198181A
CN102198181A CN 201110134691 CN201110134691A CN102198181A CN 102198181 A CN102198181 A CN 102198181A CN 201110134691 CN201110134691 CN 201110134691 CN 201110134691 A CN201110134691 A CN 201110134691A CN 102198181 A CN102198181 A CN 102198181A
Authority
CN
China
Prior art keywords
parts
blood
antithrombotic
thrombosis
eliminating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 201110134691
Other languages
Chinese (zh)
Other versions
CN102198181B (en
Inventor
陈德满
丁春忠
赵荣春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HAICHENG HOSPITAL OF CHINESE MEDICINE
Original Assignee
HAICHENG HOSPITAL OF CHINESE MEDICINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HAICHENG HOSPITAL OF CHINESE MEDICINE filed Critical HAICHENG HOSPITAL OF CHINESE MEDICINE
Priority to CN2011101346910A priority Critical patent/CN102198181B/en
Publication of CN102198181A publication Critical patent/CN102198181A/en
Application granted granted Critical
Publication of CN102198181B publication Critical patent/CN102198181B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to an antithrombotic and thrombosis-eliminating preparation, which is characterized by being prepared from the following raw material medicines in part by weight: 30 to 60 parts of astragalus, 3 to 6 parts of leech, 10 to 20 parts of safflower, 10 to 20 parts of red paeony root, 5 to 15 parts of root of red-rooted salvia and 10 to 20 parts of peach kernel. Compared with the prior art, the antithrombotic and thrombosis-eliminating preparation has the advantages that: based on the acute phase formation characteristics and pathological change of ishemic stroke, a compound Chinese medicine with effects of scattering and eliminating stasis, promoting dieresis and diminishing swelling is used to treat acute ishemic stroke; and lots of clinic tests prove that the antithrombotic and thrombosis-eliminating preparation has obvious treatment effects of preventing blood clotting, dissolving blood clots, expanding blood capillaries, relieving arteriospasm, lowering blood viscosity, improving flowing speed of microcirculating blood.

Description

The thromboembolism preventing thrombus diminishing agent
Technical field
The present invention relates to a kind of thromboembolism preventing thrombus diminishing agent for the treatment of apoplexy.
Background technology
Apoplexy also is apoplexy, is divided in the ischemic cerebral apoplexy and hemorrhagic apoplexy, and apoplexy is the general designation of Chinese medicine to acute cerebrovascular disease.The apoplexy sickness rate is along with the variation sickness rate of environment and dietary structure increases year by year at present, and the fatality rate that disables is quite high, has brought burden and economic loss to family social, so the research of apoplexy is the problem of medical profession common concern with treatment.The acute stage of cerebral infarction, generally can be carried out thromboembolism treatment in 3 hours; but most patients have missed the thrombolytic time when coming institute to go to a doctor; can only take calcium ion to pick up anti-agent and brain protection pharmaceutical treatment; in case hemostasis platelet cohesion; but often effect is unsatisfactory; the normal at present thrombolytic medicine that adopts has rt-PA or urokinase, and its side effect is bigger, causes angiorrbagia easily.
Summary of the invention
The purpose of this invention is to provide a kind of thromboembolism preventing thrombus diminishing agent,, adopt Chinese medicine partner treatment cerebral infarction according to the characteristics and the pathological change of acute cerebral ischemic stroke.
For achieving the above object, the present invention is achieved through the following technical solutions:
The medicament selection Radix Astragali of the present invention, Hirudo, Flos Carthami, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Semen Persicae make up, by these drug regimens being made each medicine effect produce synergism, can the blood circulation promoting and blood stasis dispelling embolism extinguishing, anticoagulant, acceleration microcirculation, blood viscosity lowering, prevent that microthrombus from forming again, improve the acute cerebral ischemic stroke disturbance of cerebral circulation.
The Radix Astragali of wherein selecting for use, warp warm in nature, as to return the spleen lung has the stagnant effect of QI invigorating row, is adapted to numb limbs and tense tendons, the hemiplegia of blood stagnancy due to deficiency of QI, has played the merit of " the capable then blood of gas is capable, qi being the governor of blood " in this side; Hirudo, Liver Channel is put down, returned to salty in the mouth hardship, property, this product is salty can walk blood, bitter can drop-down, go into Liver Channel, be removing blood stasis repercussive good medicine, modern pharmacological research, Hirudo contains hirudin, can prevent blood coagulation, blood clot dissolving, the expansion blood capillary, alleviate arteriospasm, blood viscosity lowering, microcirculation improvement; Flos Carthami, acrid in the mouth, warm in nature, the warp of GUIXIN liver is the product of promoting blood circulation to restore menstrual flow blood stasis dispelling, modern pharmacological research has protective effect to the ischemic hypoxia brain injury; Radix Paeoniae Rubra has the effect of clearing away heat and cooling blood blood stasis dispelling, and modern pharmacological research has the anti-platelet aggregation effect; Radix Salviae Miltiorrhizae, bitter in the mouth, cold nature, GUIXIN liver two warps, its function blood circulation promoting and blood stasis dispelling stimulates the menstrual flow, and modern pharmacological research is thought can anticoagulant, activates fibrinolytic, quickens the microcirculation velocity of blood flow; Semen Persicae, bitter but sweet flavor, property is put down, GUIXIN liver, large intestine channel, bitter can drop-down leading down with removing blood stasis with potent drugs, sweet energy and smooth QI and blood are used this medicine with tissue regeneration promoting always so clots absorbing stimulates the menstrual flow.
The consumption that medicine of the present invention is formed is groped to sum up out through the inventor in a large number, and each amounts of components all has better curative effect in the following weight parts scope:
Radix Astragali 30-60 part, Hirudo 3-6 part, Flos Carthami 10-20 part, Radix Paeoniae Rubra 10-20 part, Radix Salviae Miltiorrhizae 5-15 part, Semen Persicae 10-20 part.
Be preferably: Radix Astragali 30g, Hirudo 5g, Flos Carthami 15g, Radix Paeoniae Rubra 15g, Radix Salviae Miltiorrhizae 10g, Semen Persicae 15g.
The present invention can adopt the conventional method of Chinese medicine preparation to make any conventional oral preparations, for example can be with these crude drug decocting together, and the condensed water decocting liquid is oral then; Can also refine concentrated pill, crude drug is cleaned, dries, pulverize, sterilize, sieve, add honey then, close stick together, pill; Can also make powder, crude drug be cleaned dried, pulverize then, sterilize, sieve, insert in the Capsules.
Compared with prior art, the invention has the beneficial effects as follows: according to the characteristics and the pathological change of acute cerebral ischemic stroke formation, utilize the effect of the blood stasis dispelling of Chinese medicine composition medicine dissipating blood stasis, dampness removing, detumescence, be used for the treatment of the acute stage cerebral infarction, by a large amount of clinical trial checkings, has the blood coagulation of preventing, blood clot dissolving, the expansion blood capillary is alleviated arteriospasm, blood viscosity lowering, the significant curative effect of microcirculation improvement velocity of blood flow.
The specific embodiment
Be described further of the present invention below in conjunction with specific embodiment:
The present invention treats the clinical observation of cerebral infarction
1, physical data
Accept outpatient service and inpatient 800 examples for medical treatment, wherein male 500 examples, women 300 examples, men and women's ratio 5: 3, age 40-50 year 80 examples, 50-60 year 420 examples, 60-70 year 200 examples, 100 examples more than 70 years old.
2, diagnostic criteria, refer to go into arteries and veins with reference to " national standard is used tcm internal medicine disease treatment routine " cerebral infarction because of blood stasis expectorant is turbid, block due to the brain network, with hemiplegia crooked mouth and tongue, dysphonia, dysphagia, choke cough, hemianopsia aphasia etc. is the cardinal symptom disease, is equivalent to the said cerebral infarction of western medicine.
(1) Acute onset plays morbidity morning, or aprowl occurs clinical symptoms such as hemiplegia suddenly, good sending out in middle age; How chronic patient falls ill under states such as nighttime sleep or rest, good being sent out old age, and the male is more.
(2) before the morbidity, minority has headache dizzy or tendency such as numb limbs and tense tendons is arranged, and hemiplegia occurs after sick the sending out, dysphonia, choke cough, symptoms such as dysphagia, facial hemiparalysis, clumsy in one's movement, the instability of gait of sick the lighter, general unconscious obstacle.
(3) body temperature is breathed no significant change, and blood pressure can have rising.
3, auxiliary examination: Cranial Computed Tomography, scanning can not have obvious low-density kitchen range an acute stage, and CT scan can show the low-density focus of infarct after 24 hours, and magnetic resonance can be found focus of infarct in early days.
4, Therapeutic Method:
Concentrated pill, oral 3 times of every day, each 6 grams; Fry in shallow oil soup and concentrate, oral each 100 milliliters, day 3 times; Powder and capsule, days 3 times oral, one time 6, every 0.6 gram, two weeks were a course of treatment, logotype 2-3 course of treatment.
5, efficacy assessment standard
(1) cure: treatment back hemiplegia muscular strength, aphasis etc. recover normal, and life is all taken care of oneself;
(2) take a turn for the better: treatment back hemiplegia muscular strength all improves II level, life partial self-help;
(3) invalid: no change before and after the treatment.
6, therapeutic outcome (seeing Table 1)
Table 1 is observation of curative effect after treating
Figure BDA0000063245220000031
In a word, in six weeks, with Drug therapy cerebral infarction 800 examples of the present invention, the result cures 580 examples, cure rate 72.5%, 190 examples that take a turn for the better, invalid 30 examples, total effective rate 96.25%.
Embodiment 1
The condensed water decocting liquid preparation of medicine of the present invention
Get it filled Radix Astragali 30g, Hirudo 5g, Flos Carthami 15g, Radix Paeoniae Rubra 15g, Radix Salviae Miltiorrhizae 10g, Semen Persicae 15g add water to 600 milliliters together with raw material, soak 30 minutes, and water boiling concentration to 300 milliliter is divided 3 times oral (daily dose).
Embodiment 2
The concentrated pill preparation of medicine of the present invention
Get Radix Astragali 350g, Hirudo 50g, Flos Carthami 140g, Radix Paeoniae Rubra 140g, Radix Salviae Miltiorrhizae 140g, Semen Persicae 140g, crude drug is cleaned, dries, pulverize then, sterilize, sieve, the 960g that gets it filled altogether adds honey in 1: 1 ratio, adds sweet 960g, closes the 1920g that sticks together, make 320 ball finished products, every ball 6g.
Embodiment 3
The powder and capsule preparation of medicine of the present invention
Get it filled Radix Astragali 30g, Hirudo 3g, Flos Carthami 10g, Radix Paeoniae Rubra 10g, Radix Salviae Miltiorrhizae 15g, Semen Persicae 10g clean medicine and dry, and pulverize then, sterilize, sieve, the 78g that gets it filled altogether, consume 15%, surplus only 66g, average 110 Capsuleses of packing, every 0.6g.

Claims (2)

1. the thromboembolism preventing thrombus diminishing agent is characterized in that, it comprise following bulk drugs by weight ratio make:
Radix Astragali 30-60 part, Hirudo 3-6 part, Flos Carthami 10-20 part,
Radix Paeoniae Rubra 10-20 part, Radix Salviae Miltiorrhizae 5-15 part, Semen Persicae 10-20 part.
2. thromboembolism preventing thrombus diminishing agent according to claim 1 is characterized in that, wherein each raw material medicines in portions by weight preferred proportion is:
Radix Astragali 30g, Hirudo 5g, Flos Carthami 15g, Radix Paeoniae Rubra 15g, Radix Salviae Miltiorrhizae 10g, Semen Persicae 15g.
CN2011101346910A 2011-05-24 2011-05-24 Antithrombotic and thrombosis-eliminating preparation Active CN102198181B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2011101346910A CN102198181B (en) 2011-05-24 2011-05-24 Antithrombotic and thrombosis-eliminating preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011101346910A CN102198181B (en) 2011-05-24 2011-05-24 Antithrombotic and thrombosis-eliminating preparation

Publications (2)

Publication Number Publication Date
CN102198181A true CN102198181A (en) 2011-09-28
CN102198181B CN102198181B (en) 2012-11-21

Family

ID=44659336

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011101346910A Active CN102198181B (en) 2011-05-24 2011-05-24 Antithrombotic and thrombosis-eliminating preparation

Country Status (1)

Country Link
CN (1) CN102198181B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579610A (en) * 2012-04-01 2012-07-18 许从玉 Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof
CN109260368A (en) * 2018-09-26 2019-01-25 陈晓虎 The pharmaceutical composition and preparation method thereof for preventing and treating acute coronary syndrome
CN116036186A (en) * 2022-11-24 2023-05-02 湖南惜品医疗科技有限公司 Thrombolytic plaster, its preparation method and its application in treating venous thromboembolism

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1541683A (en) * 2003-11-05 2004-11-03 济宁华能制药厂 Antithrombotic Qilong Capsule

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1541683A (en) * 2003-11-05 2004-11-03 济宁华能制药厂 Antithrombotic Qilong Capsule

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《湖北中医杂志》 20110228 谢长宏,段正富 抗栓通络丸的制备及临床应用 75-76 1-2 第33卷, 第2期 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579610A (en) * 2012-04-01 2012-07-18 许从玉 Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof
CN102579610B (en) * 2012-04-01 2013-09-11 李伟丽 Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof
CN109260368A (en) * 2018-09-26 2019-01-25 陈晓虎 The pharmaceutical composition and preparation method thereof for preventing and treating acute coronary syndrome
CN109260368B (en) * 2018-09-26 2022-06-10 江苏省中医院 Pharmaceutical composition for preventing and treating acute coronary syndrome and preparation method thereof
CN116036186A (en) * 2022-11-24 2023-05-02 湖南惜品医疗科技有限公司 Thrombolytic plaster, its preparation method and its application in treating venous thromboembolism
CN116036186B (en) * 2022-11-24 2024-02-13 湖南惜品医疗科技有限公司 Thrombolytic plaster, its preparation method and its application in treating venous thromboembolism

Also Published As

Publication number Publication date
CN102198181B (en) 2012-11-21

Similar Documents

Publication Publication Date Title
CN101254272A (en) Promoting coronary circulation and embolism resistance medicament
CN103432390B (en) Medicament for treating coronary heart disease and preparation method thereof
CN103536858B (en) Medicine for treating rheumatoid arthritis
CN102626449A (en) Capsule for treating apoplexy hemiplegia
CN104940810A (en) Traditional Chinese medicine composition for treating angina
CN102512627B (en) Traditional Chinese medicine composition for postoperative lung cancer
CN102198181B (en) Antithrombotic and thrombosis-eliminating preparation
CN102988649B (en) Medicament for treating chronic bronchitis and preparation method of medicament
CN104083728B (en) The processing method of anticancer dispersing tumor concentrated pill
CN102836338B (en) Chinese medicament for treating cardia-cerebrovascular diseases
CN102973841B (en) Traditional Chinese medicine used for treating arthromeningitis
CN104645078A (en) Traditional Chinese medicine composition for treating migraine
CN104013836B (en) A kind of Chinese medicine composition treating cerebral apoplexy sequela
CN103585414B (en) Pharmaceutical composition for treating sciatica and osteoporosis
CN102824506B (en) Traditional Chinese medicine preparation for treating aplastic anemia
CN105106758A (en) Traditional Chinese medicine composition for treating phlegm and blood stasis type dizziness
CN104997956A (en) Behcet's syndrome and treatment drug thereof
CN104524461A (en) Medicine composition for treating myocarditis and application thereof
CN104117018A (en) Traditional Chinese medicine composition for treating coronary heart disease
CN104189615B (en) Traditional Chinese medicine preparation for treating metrorrhagia and metrostaxis, and preparation method of traditional Chinese medicine preparation
CN105288422A (en) Traditional Chinese medicine preparation used for treating eilema syndromes and preparation method
CN105079768A (en) Traditional Chinese medicine composition for treating coronary heart disease caused by syndrome of phlegm obstruction
CN105213880A (en) A kind of Chinese medicine composition for the treatment of Liver and kidney void initiation cerebral blood supply insufficiency
CN103251764B (en) A kind of Chinese medicine composition for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof
CN104056196A (en) Traditional Chinese medicine composition for treating bradycardia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant